ACI 340B Management

340B manufacturer claims data requirements are expanding in 2026!

As of June, ten manufacturers have implemented or announced claims-level data submission requirements, creating new operational and compliance challenges for covered entities.

Covered entities should track effective dates, impacted products, required data fields, submission deadlines, state exemptions, vendor responsibilities, and internal data-sharing decisions.

Because each policy is manufacturer-specific, requirements should be reviewed individually before data is shared.

Stay current. Coordinate with vendors. Document decisions. Let ACI answer your questions.

Read more here: https://aci340b.com/340b-manufacturer-claims-data-requirements-2026/

This Memorial Day, ACI pauses to remember and honor the brave men and women who made the ultimate sacrifice in service to our country.

Their courage, dedication, and selflessness will never be forgotten.
As we spend time with family and friends this holiday weekend, we reflect with gratitude on the freedoms made possible by our fallen heroes.

Thank you to all who have served and sacrificed!

340B covered entities are facing a rapidly shifting policy landscape.

This month’s key developments include:
• Contract pharmacy laws facing new legal setbacks
• No final decision yet on a potential 340B rebate model
• More manufacturers expanding in-house claims-level data requirements
• Indiana moving to eliminate most Medicaid 340B savings
• Tennessee tightening eligibility rules for in-kind funded clinics
• HRSA appealing the child site ruling

The common theme: uncertainty is increasing, and covered entities should not wait for final federal guidance to assess risk.

Now is the time to review exposure, monitor state-specific developments, and prepare for operational impacts across pharmacy, Medicaid, and compliance workflows!

Read more here: https://aci340b.com/aci-monthly-340b-may-2026/

May the 4th Be With You… and Your 340B Program!

In a galaxy not so far away, compliance, savings, and audit readiness are the true forces behind a strong 340B program.

At ACI 340B Management, we help you stay on the light side of compliance- avoiding duplicate discounts, ensuring accurate reporting, and maximizing program integrity.

Trust the force. Trust your data. Trust ACI.

340B Update: All-Claims Submissions Are Expanding

Manufacturers like Eli Lilly, Novo Nordisk, AstraZeneca, and Bristol-Myers Squibb are now requiring all-claims data submissions for 340B utilization.

What this means:
• More detailed reporting requirements
• Non-standard, manufacturer-specific formats
• Increased compliance and operational burden

Why it matters:
Access to 340B pricing may depend on participation - and data accuracy is critical.

Next steps:
Stay informed, evaluate requests carefully, and strengthen your data processes.

Read more here: https://aci340b.com/manufacturer-trend-all-claims-submissions-for-340b-purchases/

April is recognized as Cancer Control Month, a time to highlight prevention, early detection, and access to treatment. The 340B Drug Pricing Program plays a critical, and often underappreciated role, in supporting cancer care, especially for vulnerable populations.

Many rural hospitals and safety-net providers rely on 340B to sustain oncology services.

Without 340B:
• Some hospitals may not be able to offer oncology programs at all
• Patients might need to travel long distances for care
• Delays in diagnosis and treatment could increase

340B helps keep local cancer care accessible, improving early intervention and continuity of care.

340B Landscape Update: Wins, Pressure & What’s Next

State contract pharmacy laws are gaining ground with major wins in Tennessee, Colorado, and Minnesota, while new reporting requirements and manufacturer policies continue to increase pressure on covered entities.

Key takeaways:
*Courts are siding with providers
* In-house reporting requirements are expanding
*PDABs could impact 340B savings
*Compliance complexity is growing

Staying informed isn’t optional, it’s essential!

Read more in our April newsletter: https://aci340b.com/aci-monthly-april-2026/

OPAIS registration is now open!

Covered Entities can submit their registration April 1 - 15 for a July 1 go-live date.

If your organization is eligible, this is your opportunity to access significant savings on outpatient medications and strengthen your ability to serve patients in need.

Questions or need assistance? Contact ACI for support at every step!

We’re heading to Big Wonderful Wyoming!

ACI is excited to exhibit at the Wyoming HFMA Spring Conference 2026, happening April 9 - 10 in Casper, WY!

Stop by our booth to connect with the ACI team! We’d love to meet you, share insights, and talk about how we’re supporting organizations in today’s evolving 340B landscape.

Let us know if you’ll be there!

Happy St. Patrick’s Day from ACI 340B Management!

Today we’re feeling a little extra lucky to support the organizations and communities we serve every day. Just like a four-leaf clover, the 340B program brings together care, access, savings, and impact-helping providers stretch resources and improve patient outcomes.

Here’s to a day filled with a bit of Irish cheer, a lot of gratitude, and continued commitment to making healthcare more accessible for all.

Stay safe, stay lucky, and don’t forget to wear your green!